Companies / ZLD

ZELIRA THERAPEUTICS LIMITED

ASX:ZLDPharmaceuticals, Biotechnology & Life Sciences
13.1M shares on issueASX (delayed) · as of 28 July 2026$0.50price · delayed—market cap · indicative
C
Dilution grade

Runway under 2 quarters; options/rights overhang 31% of shares; share count grew 10% in 24 months

Cash runway-1.2 quarters of funding
Share-count growth (24m)10.5%
Raise cadence (24m)1 cash raise
Options & rights overhang31.0% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

ZELIRA THERAPEUTICS LIMITED's ordinary share count grew 10.5% between April 2025 and July 2026, to 13M shares. The company raised capital once in the 24‑month window, a Convertible Note Issue in November 2025 for A$500K, total proceeds A$500K. Options and rights could convert into 4M new shares, equal to 31.0% of the current share count, with 0% in the money. At the March 2026 quarter the company reported A$-415K in cash and a cover figure of -1.2 quarters. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
31.0%
Max option dilution
0.0%
ITM option dilution
1
Raises · last 12 months
-1.2 qtrs
Cash cover · under 2 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 13.1M per ASX (delayed) (28 July 2026).
11.7M12.2M12.8MDec 24Sept 25July 26Cash raise · 19 Nov 2025

Cash runway

-1.2 qtrs
Less than two quarters of funding at the recent spend rate — near-term funding pressure.
$-415k available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
2 July 20263H · cancellationZLD : ORDINARY FULLY PAID11.9MAppendix 3H
1 July 20262A · quoted issueZLD : ORDINARY FULLY PAID13.1MAppendix 2A
4 Dec 20253G · unquotedORDINARY FULLY PAID11.9MAppendix 3G
22 Oct 20253H · cancellationZLD : ORDINARY FULLY PAID11.9MAppendix 3H
1 Apr 20252A · quoted issueZLD : ORDINARY FULLY PAID11.9MAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

1 cash raise in the last 24 months · 1 in the last 12 months

$500k
Convertible Note Issue
19 Nov 2025 COMPLETE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

31.0%
Total overhang · of current shares
0.0%
In the money · at current price
4.1M
Potential new shares
—
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
1 July 2026Osagie ImasogieOther1.3M——3Y notice
4 Dec 2025Dr. Donna Gentile O'DonnelOther—115k$50k3Y notice
4 Dec 2025Oludare OdumosuOther132k240k$100k3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

2 July 2026Change of Director's Interest Notice
2 July 2026Notification of cessation of securities - ZLD
1 July 2026Application for quotation of securities - ZLD
15 June 2026Chairman Loan
29 Apr 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
10 Mar 2026Director Loan
28 Jan 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
15 Jan 2026$PTransformative US$33M Fundraising into Zeliras HOPE 1 SPV
4 Dec 2025Change of Director's Interest Notice x2
4 Dec 2025Notification regarding unquoted securities - ZLD
25 Nov 2025$PZelira receives $1,070,000 R&D Tax Incentive Scheme Refund
19 Nov 2025Proposed issue of securities - ZLD
19 Nov 2025Results of Meeting
19 Nov 20252025 Annual General Meeting Presentation
27 Oct 2025$PQuarterly Activities/Appendix 4C Cash Flow Report
22 Oct 2025Notification of cessation of securities - ZLD
20 Oct 2025Letter to Shareholders
20 Oct 2025Notice of Annual General Meeting/Proxy Form
26 Sept 2025Appendix 4G
26 Sept 2025Annual Report to shareholders

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.